ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Neoadjuvant Immunotherapy for Skin Cancer

by Jennifer Fink • April 18, 2023

  • Tweet
  • Email
Print-Friendly Version

You Might Also Like

No related posts.

Explore This Issue
April 2023

Advanced squamous cell carcinoma threatened the patient’s eye. Although most cases of cutaneous squamous cell carcinoma can be effectively treated via simple excision, this patient’s cancer was large, disfiguring, and potentially life-altering, as surgical treatment would likely require enucleation.

“The standard of care for patients with locally advanced, resectable head and neck squamous cell carcinomas is surgery and radiation. But given the proximity of the pathology to critical structures, like the eye, ear, lips, and nose, surgery can be functionally devastating,” said Neil D. Gross, MD, professor and director of clinical research in the department of head and neck surgery at MD Anderson Cancer Center in Houston. “Some patients lose an eye, or an ear, or big parts of their scalp.”

Neoadjuvant immunotherapy may allow some patients with locally advanced squamous cell carcinoma to avoid disfiguring and functionally devastating surgeries. In 2017, Dr. Gross launched a small clinical trial testing immunotherapy prior to surgery and found that “with just two doses of the drug before surgery, the tumors started melting away,” he said. “For 11 out of 20 patients, by the time we went to surgery, there was no tumor left; it was completely gone. For another four patients, it was almost completely gone.” (Clin Cancer Res. 2021;27:4557–4565).

Dr. Gross and others have since conducted a phase two, confirmatory, multicenter, nonrandomized study to evaluate cemiplimab, a PD-1/PD-L1 checkpoint inhibitor, as neoadjuvant therapy in patients with resectable stage II, III, or IV cutaneous squamous cell carcinoma of the head and neck. Again, results were positive. “There was nothing left of the cancers in just over half of the patients,” Dr. Gross said. “In another handful of patients, the cancer was almost completely gone.” (N Engl J Med. 2022;387:1557–1568). Some patients were able to keep their eyes (and vision).

Will neoadjuvant immunotherapy eventually become the standard of care for patients with locally advanced, resectable squamous cell carcinoma of the head and neck? Perhaps. Additional questions must be answered first.

Here’s what’s currently known—and not yet known—about neoadjuvant immunotherapy for advanced squamous cell carcinoma.

New Treatment Options for Previously Underserved Patients

Cutaneous squamous cell carcinoma is the second most common form of skin cancer worldwide, and approximately 2% to 5% of patients present with locally advanced cancers (Clin Cancer Res. 2021;27:4557–4565). Treatment is challenging— particularly because many patients are of advanced age and have other comorbid conditions—and may be disfiguring and disabling. Approximately 30% of patients with locoregionally advanced resectable cutaneous squamous cell carcinoma eventually die of the disease, despite treatment (Clin Cancer Res. 2021;27:4557–4565). “These patients have been underserved for a long time,” Dr. Gross said.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Features, Home Slider Tagged With: HN squamous cell carcinomas, Neoadjuvant ImmunotherapyIssue: April 2023

You Might Also Like:

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Second Victims: The Effects of a Medical Error on Physicians Can Be Devastating
    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?
    • Keeping Watch for Skin Cancers on the Head and Neck
    • Complications for When Physicians Change a Maiden Name
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?
    • Vertigo in the Elderly: What Does It Mean?
    • What Happens to Medical Students Who Don’t Match?
    • Complications for When Physicians Change a Maiden Name
    • Qualitative Research Shows How Patients Feel About Quality-of-Life Issues
    • How to: A Dynamic Endonasal Columellar Strut Placement
    • Second Victims: The Effects of a Medical Error on Physicians Can Be Devastating
    • Advanced Degrees Can Help Otolaryngologists Better Understand the Business of Medicine
    • Laser Laryngeal Surgery Is Safe Under THRIVE

Polls

Have you ever been, or have you ever known someone who has been a second victim?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2023 The Triological Society. All Rights Reserved.
ISSN 1559-4939